Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.

ABSTRACT:

Unlabelled

: In recent years, immune checkpoint inhibitors have emerged as effective therapies for advanced neoplasias. As new checkpoint target blockers become available and additional tumor locations tested, their use is expected to increase within a short time. Immune-related adverse events (irAEs) affecting the endocrine system are among the most frequent and complex toxicities. Some may be life-threatening if not recognized; hence, appropriate guidance for oncologists is needed. Despite their high incidence, endocrine irAEs have not been fully described for all immunotherapy agents available. This article is a narrative review of endocrinopathies associated with cytotoxic T lymphocyte-associated antigen-4, blockade of programmed death receptor 1 and its ligand inhibitors, and

SUBMITTER: Gonzalez-Rodriguez E 

PROVIDER: S-EPMC4943391 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature